newsfilter
← Latest News
GlobeNewswire·

Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights

Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in November 2026IND filing for the Enhanced Brain Delivery™ (EBD®)